TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07186101: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis

Sponsor: Eli Lilly and Company · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 252 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,070,000

Rescue Site Savings

+$1,380,000

Unlock Full NCT07186101 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07186101 Rescue Dossier →